Shares of BioNTech SE dropped 2.4% toward a three-month low in premarket trading Monday, after the Germany-based biotechnology company, which developed a...
Shares of BioNTech SE BNTX dropped 2.4% toward a three-month low in premarket trading Monday, after the Germany-based biotechnology company, which developed a COVID-19 vaccine with partner Pfizer Inc. PFE, reported second-quarter revenue that fell well short of expectations, while swinging to a net loss that beat forecasts. The company reported a net loss of EUR190.4 million , or EUR0.79 a share, after net income of EUR1.67 billion, or EUR6.45 a share, in the year-ago period.
The company reported a net loss of EUR190.4 million , or EUR0.79 a share, after net income of EUR1.67 billion, or EUR6.45 a share, in the year-ago period. The FactSet per-share loss consensus was EUR0.83. Total revenue declined to EUR167.7 million from EUR3.20 billion, to miss the FactSet consensus of EUR628.1 million. “Write-offs by BioNTech’s collaboration partner Pfizer, Inc.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Stock Funds Are Up 16.7% for 2023The stock-market rally kept investors bullish—to a point. The Fed’s moves still will call the tune.
続きを読む »
Putin risks public wrath over extending draft, doubling war budgetReuters reported that Russia will spend over $100 billion on its military in 2023.
続きを読む »
5 things 2023’s biggest election will tell us about 2024This year's bellwether election could tell us a lot.
続きを読む »
My most anticipated laptops still coming in 2023 | Digital TrendsNow that we're over half way through the year, let's look at the most exciting laptops still to come in 2023.
続きを読む »
Pokémon TCG Value Watch: Silver Tempest In August 2023Is the Lugia V Alternate Art from PokemonTCG: Sword & Shield - SilverTempest increasing or dropping in value in August 2023? Let's see how this set is doing in the market. Pokemon
続きを読む »